Press release

Ability Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013.
Bellaterra (Barcelona, Catalonia, Spain). February 20, 2013. Ability Pharmaceuticals, SL announced today that Carles Domènech, PhD, Chief Executive Officer and co-Founder, will be presenting at the 6th Annual European Life Sciences CEO Forum on Tuesday, March 5, 2013 at the Hilton Zurich Airport Hotel, Switzerland. The conference is highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.

Dr. Domènech will present a company overview and will pursuit Ability Pharmaceuticals’s ongoing contacts with the industry and investors.

About Ability Pharmaceuticals

Ability Pharmaceuticals is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona. Current investors in the company are the specialized biotech venture capital company Inveready Capital Company, the founders and private investors.

Ability Pharmaceuticals develops highly differentiated innovative cancer drugs, with a novel mechanism of action, called Lipid Analog Therapeutics. The company has two drug candidates in development: ABTL0812, which is completing preclinical development, with planned phase Ib clinical trials in lung cancer and pancreatic cancer starting in spring 2013; and ABTL1014, expected to start preclinical development in 1Q 2013.
Developed by Web4Bio